References
- Hediger MA, Rhoads DB. (1994). Molecular physiology of sodium glucose cotransporters. Physiol Rev 74:993–1026
- Kadokura T, Saito M, Utsuno A, et al. (2011). Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int 2:172–82
- Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (2010). (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 53:3247–61
- Kanai Y, Lee WS, You G, et al. (1994). The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for d-glucose. J Clin Invest 93:397–404
- Kim GW, Chung SH. (2014). Clinical implication of SGLT2 inhibitors in type 2 diabetes. Arch Pharm Res 37:957–66
- Kurosaki E, Ogasawara H. (2013). Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol Ther 139:51–9
- Liu J, Lee T, DeFronzo R. (2012). Why Do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? Diabetes 61:2199–204
- Mizuno-Yasuhira A, Nakai Y, Gunji E, et al. (2014). A strategy for assessing potential drug–drug interactions of a concomitant agent against a drug absorbed via an intestinal transporter in humans. Drug Metab Dispos 42:1456–65
- Musso G, Gambino R, Cassader M, et al. (2012). A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44:375–93
- Rahmoune H, Thompson PW, Ward JM, et al. (2005). Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54:3427–34
- Sabolic I, Vrhovac I, Eror DB, et al. (2012). Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Physiol Cell Physiol 15:C1174–88
- Sarashina A, Koiwai K, Seman LJ, et al. (2013). Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 28:213–19
- Sasaki T, Seino Y, Fukatsu A, Sakai S, et al. (2014). Safety, Pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther 31:345–61
- Scheen AJ. (2014). Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clin Pharmacokinet 53:295–304
- Schwab D, Portron A, Backholer Z, et al. (2013). A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans. Clin Pharmacokinet 52:463–73
- Seino Y. (2014). Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 15:2741–9
- Washburn WN, Poucher SM. (2013). Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 22:463–86
- Yamamoto K, Uchida S, Kitano K, et al. (2011). TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 164:181–91